Singapore Actinic Keratosis Therapeutics Market Report 2022 to 2030

Singapore Actinic Keratosis Therapeutic Market Analysis

$ 3999

The Singapore Actinic Keratosis Therapeutic Market is expected to grow at a CAGR of 5.5% during the forecast period, rising from $8 Mn in the year 2022 and reaching $13 Mn by the year 2030. Factors contributing to the Singapore Actinic Keratosis Therapeutic Market growth include rising healthcare expenditures, an aging population, changing weather patterns, and patient preferences for convenient and effective treatment modalities. Key players in the Singapore Actinic Keratosis Therapeutic Market include LEO Pharma, Galderma, Sun Pharmaceuticals, Bayer, Alma Lasers, Syneron Candela, Novartis and Bausch Health among others

ID: IN10SGPH422 CATEGORY: Pharmaceuticals GEOGRAPHY: Singapore AUTHOR: Netal Patel

Buy Now

Singapore Actinic Keratosis Therapeutic Market Executive Summary

The Singapore Actinic Keratosis Therapeutic Market is expected to grow at a CAGR of 5.5% during the forecast period, rising from $8 Mn in 2022 to $13 Mn by 2030.

Actinic keratoses (AKs), also referred to as solar keratoses, are scaly or keratotic patches, bumps, or plaques that form due to abnormal growth of keratinocytes in the epidermis caused by prolonged exposure to ultraviolet (UV) radiation, whether from the sun or indoor tanning, making it the most common precancerous condition on sun-damaged skin. The condition, also known as solar keratosis, results from extended exposure to UV radiation. Various effective treatments for AK include topical medications like fluorouracil, imiquimod, tirbanibulin, and diclofenac; destructive therapies such as cryosurgery, surgery, dermabrasion, and photodynamic therapy (PDT); as well as field ablation methods like chemical peels and laser resurfacing. The choice of treatment is influenced by factors like the number and distribution of lesions and the characteristics of the lesions.

Singapore's dermatological outpatients have an AK prevalence of 5.6%, which increased to 14.57% among those over the age of 70. Given that the frequency of AK typically rises with age and cumulative sun exposure, our study is consistent with global trends. A significant section of the populace in Singapore is exposed to excessive UV radiation due to its sunny climate and outdoor lifestyle, which is the main risk factor for AK. Factors contributing to the Singapore Actinic Keratosis Therapeutic Market include rising healthcare expenditures, an aging population, changing weather patterns, and patient preferences for convenient and effective treatment modalities.

Key players in the Singapore Actinic Keratosis Therapeutic Market include LEO Pharma, Galderma, Sun Pharmaceuticals, Bayer, Alma Lasers, Syneron Candela, Novartis, and Bausch Health, among others.

Market Dynamics

Market Growth Drivers

The market is being driven by the rising prevalence of AK and the growing need for treatment as more individuals become aware of the problem. An aging population means that more people are getting closer to the over-50-year-old peak risk age for AK. Changing weather patterns and greater sun exposure from leisure activities have an impact on the development of AK. Market trends are significantly influenced by patient preferences for certain treatment modalities, including elements like convenience, usability, and low side effects. Their adoption of cutting-edge treatment alternatives propels the market's expansion.

The Singapore Actinic Keratosis Therapeutic Market is expanding as a result of many reasons. Continuous research and development leads to more effective treatments for AK, which drives market expansion. Patients and healthcare professionals are adopting novel therapies as a consequence of their enhanced effectiveness and safety profiles. Novel diagnostic tools and tailored therapeutics are examples of technological breakthroughs that improve AK care and support market expansion.

Market Restraints

Apart from the factors driving the market, limitations such as different levels of awareness also have an impact on it. Despite increasing awareness of AK, some people may not realize what the condition is or how important early intervention is. This might lead to delays in diagnosis and a decline in market demand. Some healthcare practitioners may need additional information and training about the most recent alternatives for AK treatment and whether or not they are suited for different patient profiles. This might hinder the best practices for prescribing and limit the market's acceptance of new therapies.

The side effects of a certain therapy may discourage some patients, or they may prefer less intrusive options. This might have an effect on adoption rates and market growth. Insurance companies and healthcare providers may choose less expensive, more sophisticated treatments over more costly, more sophisticated ones, such as generic topical creams. This might stop more costly but cutting-edge therapies from hitting the market. Strict legal restrictions and protracted approval processes seem to lessen the demand. Some manufacturers are discouraged from introducing innovative AK therapies to the Singapore market since it can be very costly and time-consuming.

Healthcare Policies and Regulatory Landscape

Singapore's healthcare system is financed by a combination of sources, including nationalized life insurance and contributions from working citizens' Central Provident Funds (CPF). Key policy challenges, including postponing the start of chronic diseases, boosting home-based care for managing chronic diseases, and coordinating care for individuals with high needs, have all been addressed by the government via the implementation of various initiatives. The aging population, which will double by 2030, and advancements in medicine are being accommodated by the system. Singapore is focusing on value-based care and the sharing of best practices while creating integrated, patient-centered strategies for the management of chronic illnesses. The Health Sciences Authority (HSA) is in charge of Singapore's therapeutic product regulatory environment. In Singapore, applications for the registration of therapeutic medicines fall into two categories: new drug applications (NDAs) and generic drug applications (GDAs). Businesses must pass regulatory inspections and screenings in order to be granted a license to produce therapeutic products. Clinical studies are governed by the HSA, and before any therapeutic product is given in Singapore, it must be registered. It is a strict yet efficient system that strikes a balance between timely access to cutting-edge therapies and patient safety.

Competitive Landscape

Key Players

LEO Pharma
Galderma
Sun Pharmaceutical Industries
Bayer
Alma Lasers
Syneron Candela
Novartis
Bausch Health
GlaxoSmithKline
Almirall

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Singapore Actinic Keratosis Market Segmentation

By Treatment Type

Topical Treatment
Procedural Modality
Photodynamic Therapy
Others

By Drug Class

Nucleoside Metabolic Inhibitor
Immune Response Modifiers
NSAIDs
Photo enhancer
Other Drug Classes

By Distribution Channel

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Providers

By Disease Type

Clinical AK
Subclinical AK

By End User

Hospitals
Private Dermatology Clinics
Laser Therapy Centres
Cancer Treatment Centres
Spas and Rejuvenation Centres
Homecare

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.